Metabolic Reprogramming in Cardiometabolic Syndrome: Mechanisms, Biomarkers, and Therapeutic Approaches

• Metabolic reprogramming is a central mechanism driving the initiation and progression of cardiometabolic syndrome, beyond traditional hormonal and hemodynamic factors. • Multiomics platforms (genomics, proteomics, metabolomics, metagenomics) are pivotal for identifying novel biomarkers and therapeutic targets in CMS. • Obesity-induced adipose tissue dysfunction, inflammation, and ectopic lipid accumulation are key triggers of metabolic reprogramming and CMS pathophysiology. • Restoring metabolic flexibility through pharmacological interventions represents a promising therapeutic strategy to halt CMS progression.